Compare iShares Core S&P 500 ETF (IVV) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs Twist Bioscience Corp — how do they compare? iShares Core S&P 500 ETF trades at $780.07 (market cap $897.20B), while Twist Bioscience Corp trades at $165.06 (market cap $10.08B). The key difference: iShares Core S&P 500 ETF is far larger — about 89× Twist Bioscience Corp's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Twist Bioscience Corp for 27 Days on average.
| IVV | TWST | |
|---|---|---|
Market Cap | $897.20B | $10.08B |
Volume | 4,580,672 | 4,229,037 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $205.00 |
52-Week Low | $634.93 | $25.45 |
Typical Hold Time | 46 Days | 27 Days |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $780.6, down 0.25% on the day. Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions near-term. The ETF benefits from diversified exposure to large-cap US equities, with recent news highlighting strong corporate earnings growth expectations of 35% for 2026. Market sentiment remains mixed amid concerns about valuation and profit growth normalization.
Outlook remains cautiously optimistic given the S&P 500's historical bullish seasonal patterns and strong institutional support. Key risks include elevated Treasury yields, concentration in top holdings, and potential earnings growth deceleration to 15% in 2027. The ETF's low-cost structure and broad market exposure provide defensive characteristics during market volatility.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
